PASG vs ACAD vs JPM vs PRAX vs BAC

For growth investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 4x trailing P/E (55. 6x forward), making it the more compelling value choice. Analysts rate ACADIA Pharmaceuticals Inc. (ACAD) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACADIA Pharmaceuticals Inc.

(ACAD) is the cheapest at 9. 4x versus JPMorgan Chase & Co. at 16. 2x. On forward P/E, Bank of America Corporation is actually cheaper at 12. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Bank of America Corporation wins at 0. 82x versus JPMorgan Chase & Co. 's 0. 83x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +135. 5%, compared to -98. 1% for Passage Bio, Inc. (PASG). Over 10 years, the gap is even starker: JPM returned +481. 2% versus PASG's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Bank of America Corporation (BAC) is the lower-risk stock at 0.

83β versus Passage Bio, Inc. 's 3. 30β — meaning PASG is approximately 299% more volatile than BAC relative to the S&P 500. On balance sheet safety, Praxis Precision Medicines, Inc. (PRAX) carries a lower debt/equity ratio of 0% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.

(ACAD) is pulling ahead at 11. 9% versus -100. 0% for Praxis Precision Medicines, Inc. (PRAX). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -32. 0% for Praxis Precision Medicines, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus 0. 0% for Praxis Precision Medicines, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 0. 0% for PRAX. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Bank of America Corporation (BAC) is the more undervalued stock at a PEG of 0. 82x versus JPMorgan Chase & Co. 's 0. 83x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bank of America Corporation (BAC) trades at 12. 6x forward P/E versus 55. 6x for ACADIA Pharmaceuticals Inc. — 43. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRAX: 106. 9% to $584. 00.

In this comparison, BAC (2.

3% yield), JPM (1. 8% yield) pay a dividend. PASG, ACAD, PRAX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, JPMorgan Chase & Co.

(JPM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87), 1. 8% yield, +481. 2% 10Y return). Passage Bio, Inc. (PASG) carries a higher beta of 3. 30 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (JPM: +481. 2%, PASG: -98. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PASG (Healthcare) and ACAD (Healthcare) and JPM (Financial Services) and PRAX (Healthcare) and BAC (Financial Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PASG is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; JPM is a large-cap deep-value stock; PRAX is a small-cap quality compounder stock; BAC is a large-cap deep-value stock. JPM, BAC pay a dividend while PASG, ACAD, PRAX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.